Table 1.
Variable | Value for posaconazole patients (n = 86) |
---|---|
Demographics | |
Median age [yr (range)] | 51 (18–79) |
No. of males/females | 50/36 |
Median wt [kg (range)a] | 71 (38–122) |
No. with indication for therapyb: | |
Antifungal prophylaxis | 72 |
Proven IFI | 6 |
Probable IFI | 3 |
Possible IFI | 3 |
Empirical therapy | 2 |
No. with underlying condition: | |
Acute myeloid leukemia | 38 |
Acute lymphoblastic leukemia | 11 |
Non-Hodgkin's lymphoma | 8 |
Myelodysplastic syndrome | 6 |
Multiple myeloma | 4 |
Diabetes mellitus type 2 | 4 |
Chronic lymphocytic leukemia | 3 |
Otherc | 12 |
Weight was available for 85/86 patients.
Patients receiving posaconazole for treatment of a fungal infection defined according to the 2008 EORTC/MSG guidelines (8).
Myelofibrosis (2 patients), Hodgkin's lymphoma (1 patient), acute biphenotypic leukemia (1 patient), gray-zone lymphoma (1 patient), T-polylymphocytic leukemia (1 patient), chronic myeloid leukemia (1 patient), aplastic anemia (1 patient), HIV positivity (1 patient), rheumatoid arthritis (1 patient), Crohn's disease (1 patient), and none (histoplasma) (1 patient).